Allergy Thera. Regulatory News (AGY)

7 Nov 2005 07:00

Allergy Therapeutics PLC07 November 2005 Allergy Therapeutics plc strengthens board with experienced pharmaceutical development professional Allergy Therapeutics today announces the appointment to the board of Dr.Virinder Nohria as a non-executive director. Dr. Nohria, aged 51, works as a strategic consultant in international drugdevelopment. He has lead teams in many successful interactions with regulatorybodies in several countries, particularly the US FDA. Dr. Nohria served as ChiefMedical Officer and Vice President of Xcel Pharmaceuticals, Inc., a US specialtypharmaceutical company until the sale of the company to Valeant PharmaceuticalInternational in early 2005. Prior to joining Xcel, Dr. Nohria held severalpositions in biotechnology and pharmaceutical companies including UCB Pharma andEli Lilly and Company. Dr. Nohria is a board certified paediatric neurologistand received his medical degree from Cambridge University and doctorate inneuropharmacology from University of Bradford. He is currently based in the USand has affiliations with Emory and Duke Universities. Ignace Goethals, Chairman of Allergy Therapeutics plc said: "I am delighted that Virinder has agreed to join our board as a non-executivedirector. His expertise in drug development and dealing with the FDA will be aninvaluable support to our excellent and growing internal R&D team as our newMPL-based vaccines move through the late phases of clinical trials" Virinder Nohria commented: "Allergy Therapeutics is an emerging pharmaceutical company with a unique modernpipeline in the interesting field of allergy vaccination with great potential.There is real unmet medical need here and I look forward to being involved withthe company." For further information:Allergy Therapeutics 01903 844720Keith Carter, Chief Executive Bell Pottinger 020 7861 3232Dan de Belder / Emma Charlton This information is provided by RNS The company news service from the London Stock Exchange